Heier JS, Brown DM, Chong V, Korobelnik J, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48. https://doi.org/10.1016/j.ophtha.2012.09.006.

Article  PubMed  Google Scholar 

Martin DF, Ying G, Grunwald JE, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908. https://doi.org/10.1056/NEJMOA1102673/SUPPL_FILE/NEJMOA1102673_DISCLOSURES.PDF.

Article  CAS  PubMed  Google Scholar 

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31. https://doi.org/10.1056/NEJMoa054481.

Article  CAS  PubMed  Google Scholar 

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44. https://doi.org/10.1056/NEJMoa062655.

Article  CAS  PubMed  Google Scholar 

Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98. https://doi.org/10.1016/j.ophtha.2012.03.053.

Article  PubMed  Google Scholar 

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411. https://doi.org/10.1016/j.ophtha.2012.04.015.

Article  PubMed  Google Scholar 

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258–67. https://doi.org/10.1016/S0140-6736(13)61501-9.

Article  CAS  PubMed  Google Scholar 

Ho AC, Busbee BG, Regillo CD, Heier JS, Lindstrom RL, Orr SC, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181–92. https://doi.org/10.1016/J.OPHTHA.2014.05.009.

Article  PubMed  Google Scholar 

Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046–56. https://doi.org/10.1016/J.OPHTHA.2012.10.014.

Article  PubMed  Google Scholar 

Bressler NM, Doan QV, Varma R, Lee PP, Suñer IJ, Dolan C, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol (Chic, Ill 1960). 2011;129:709–17. https://doi.org/10.1001/ARCHOPHTHALMOL.2011.140.

Article  Google Scholar 

Zarranz-Ventura J, Parrado-Carrillo A, Nguyen V, Sararols L, Garay-Aramburu G, Puzo M, et al. Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes. Clin Exp Ophthalmol. 2022;50:312–24. https://doi.org/10.1111/CEO.14054.

Article  PubMed  Google Scholar 

Ozawa Y, Veritti D, Sarao V, Soppelsa V, Danese C, Chhablani J, et al. Clinical medicine managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression. J Clin Med. 2022. https://doi.org/10.3390/jcm11020325.

Martin-Pinardel R, Izquierdo-Serra J, De Zanet S, Parrado-Carrillo A, Garay-Aramburu G, Puzo M, et al. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database. Br J Ophthalmol. 2024;108:253–62. https://doi.org/10.1136/bjo-2022-322297.

Article  PubMed  Google Scholar 

Recommendations | Age-related macular degeneration | Guidance | NICE.

Yeung L, Hsieh YT, Yang CH, Chen LJ, Chen SJ, Cheng CK, et al. Management of neovascular age-related macular degeneration: Taiwan expert consensus. J Formos Med Assoc. 2021;120:2061–71. https://doi.org/10.1016/J.JFMA.2021.06.012.

Article  PubMed  Google Scholar 

Gillies MC, Walton R, Liong J, Arnold JJ, McAllister I, Moriet N, et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! project. Retina. 2014;34:188–95. https://doi.org/10.1097/IAE.0b013e318296b271.

Article  PubMed  Google Scholar 

Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247:137–42. https://doi.org/10.1007/s00417-008-0926-0.

Article  CAS  PubMed  Google Scholar 

Shona O, Gupta B, Vemala R, Sivaprasad S. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. Clin Exp Ophthalmol. 2011;39:5–8. https://doi.org/10.1111/J.1442-9071.2010.02424.X.

Article  PubMed  Google Scholar 

Rahimy E, Rayess N, Ho AC, Regillo CD. Treatment outcomes for neovascular age-related macular degeneration patients with initial vision better than 20/40 using a treat-and-extend regimen. Retina. 2016;36:875–80. https://doi.org/10.1097/IAE.0000000000000814.

Article  CAS  PubMed  Google Scholar 

Langelaan M, De Boer MR, Van Nispen RMA, Wouters B, Moll AC, Van Rens GHMB. Impact of visual impairment on quality of life: a comparison with quality of life in the general population and with other chronic conditions. Ophthalmic Epidemiol. 2007;14:119–26. https://doi.org/10.1080/09286580601139212.

Article  PubMed  Google Scholar 

Fenwick EK, Ong PG, Man REK, Cheng CY, Sabanayagam C, Wong TY, et al. Association of Vision Impairment and Major Eye Diseases With Mobility and Independence in a Chinese Population. JAMA Ophthalmol. 2016;134:1087–93. https://doi.org/10.1001/JAMAOPHTHALMOL.2016.2394.

Article  PubMed  Google Scholar 

Veritti D, Sarao V, Soppelsa V, Danese C, Chhablani J, Lanzetta P. Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression. J Clin Med. 2022;11. https://doi.org/10.3390/JCM11020325.

Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:1837–45. https://doi.org/10.1016/j.ophtha.2015.05.010.

Article  PubMed  Google Scholar 

Tufail A. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity manuscript no. 2013-568. Ophthalmology. 2014;121:1092–101. https://doi.org/10.1016/j.ophtha.2013.11.031.

Article  Google Scholar 

Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The neovascular age-related macular degeneration database: Report 2: Incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014;121:1966–75. https://doi.org/10.1016/j.ophtha.2014.04.026.

Article  PubMed  Google Scholar 

Izquierdo-Serra J, Martin-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sanchez-Monroy J, et al. Macular neovascularization type influence on anti-VEGF intravitreal therapy outcomes in age-related macular degeneration. Ophthalmol Retin. 2024;8:350–9. https://doi.org/10.1016/j.oret.2023.10.022.

Article  Google Scholar